About Spero Therapeutics
Spero Therapeutics is a company based in Cambridge (United States) founded in 2013 by Milind Deshpande. Spero Therapeutics has raised $114.7 million across 13 funding rounds from investors including Pfizer, HHS and RA Capital. The company has 32 employees as of December 31, 2024. Spero Therapeutics offers products and services including Tebipenem HBr and SPR720. Spero Therapeutics operates in a competitive market with competitors including Nabriva, Melinta Therapeutics, Iterum Therapeutics, Adaptive Phage Therapeutics and Paratek Pharma, among others.
- Headquarter Cambridge, United States
- Employees 32 as on 31 Dec, 2024
- Founders Milind Deshpande
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Spero Therapeutics, Inc.
-
Annual Revenue
$27.4 M (USD)-71.68as on Dec 31, 2024
-
Net Profit
-$68.57 M (USD)-400.65as on Dec 31, 2024
-
EBITDA
-$93.06 M (USD)-562.82as on Dec 31, 2024
-
Total Equity Funding
$114.7 M (USD)
in 13 rounds
-
Latest Funding Round
$9 M (USD), Post-IPO
Nov 14, 2022
-
Investors
Pfizer
& 14 more
-
Employee Count
32
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Spero Therapeutics
Spero Therapeutics is a publicly listed company on the NASDAQ with ticker symbol SPRO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Spero Therapeutics
Spero Therapeutics offers a comprehensive portfolio of products and services, including Tebipenem HBr and SPR720.
Investigational oral carbapenem for urinary tract infections treatment.
Potential treatment for multidrug-resistant bacterial infections.
People of Spero Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
18 people
Software Development Team
4 people
Operations Team
3 people
Data Analysis and Operations Team
2 people
Finance and Accounting
2 people
Human Resources and Administration
2 people
Product Management Team
1 people
Clinical Team
1 people
Unlock access to complete
Funding Insights of Spero Therapeutics
Spero Therapeutics has successfully raised a total of $114.7M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $9 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Spero Therapeutics
Spero Therapeutics has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, HHS and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund focused on solutions targeting resistant micro-organisms
|
Locked | Locked | Locked | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Locked | Locked | Locked | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked |
Investor details for Spero Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Spero Therapeutics
Investment portfolio details for Spero Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Spero Therapeutics
Detailed financials for Spero Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Spero Therapeutics Comparisons
Peer comparison for Spero Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Spero Therapeutics
Spero Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nabriva, Melinta Therapeutics, Iterum Therapeutics, Adaptive Phage Therapeutics and Paratek Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| Locked | Locked | Locked |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| Locked | Locked | Locked |
Developer of antibiotics for MDR infections
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| Locked | Locked | Locked |
Therapeutics for antimicrobial resistant infections are developed.
|
Detailed competitors of Spero Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Spero Therapeutics
Complete news archive for Spero Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Spero Therapeutics
Spero Therapeutics was founded in 2013.
Spero Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Spero Therapeutics is a funded company, having raised a total of $114.7M across 13 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Spero Therapeutics is 32.
Annual revenue of Spero Therapeutics is $27.4M as on Dec 31, 2024.
Developer of therapeutics for drug-resistant bacterial infections. It offers a portfolio of novel product candidates which includes Tebipenem HBr, an oral carbapenem for pediatric infections, SPR720, an oral antimicrobial agent for the treatment of non-tuberculous mycobacterial lung disease, and SPR206, an intravenous (IV)-administered next-generation polymyxin analog for gram-negative bacterial infections.
Spero Therapeutics's top competitors include Melinta Therapeutics, Vedanta Biosciences and Cubist Pharmaceuticals.
Spero Therapeutics offers Tebipenem HBr and SPR720.
Yes, Spero Therapeutics is publicly traded on NASDAQ under the ticker symbol SPRO.
Spero Therapeutics has 15 investors. Key investors include Pfizer, HHS, RA Capital, CARB-X, and Atlas Venture.
The ticker symbol of Spero Therapeutics is SPRO on NASDAQ.